FDA Perspectives: Common Deficiencies in Abbreviated New Drug Applications: Part 2: Description, Composition, and Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Perspectives: Common Deficiencies in Abbreviated New Drug Applications: Part 2: Description, Composition, and Excipients
FDA chemistry reviewers in the Office of Generic Drugs provide an overview of common deficiences cited throughout the Chemistry, Manufacturing, and Controls section of ANDAs.


Pharmaceutical Technology
Volume 34, Issue 8, pp. 45-51

Drug product composition information. Very few deficiencies and comments are cited with regard to the information presented in the composition tables. If cited, these include not providing the percent of each excipient (e.g., w/w %) in the formulation. The intent of this question is to clearly provide the reviewer the intended function of the multifunctional excipients in the formulation at the proposed w/w % level. This information is critical to the assessment of the formulation as it is well documented that changing the w/w % of multifunctional excipient in the formulation can potentially change the function. In cases of multistrength products, it also provides the information on the dose proportionality over the range of strengths.

An applicant should provide a list, for each product strength where applicable, the quantitative composition, function of excipient, grade (e.g., Avicel PH 101 etc.), the standard (e.g., US Pharmcopeia, National Formulary, Food Chemicals Codex, etc.), and origin as applicable (e.g., vegetable or animal source) of each component. This list should include all materials that are used throughout the process including organic and aqueous solvents and processing aids used in the manufacturing process and are removed during the process (e.g., water, alcohol, nitrogen, etc.). Information for all ingredients including specifications and certificates of analysis should be provided in 3.2.P.4. The quantitative information for unit dose must specify a unit of measure for all other ingredients contained in the product.

Another issue that may need to be addressed is with regard to the justification of the excipient function in the formulation. The reported function should be based on documented evidence and the design of the product. For multifunctional excipients, the sponsor should provide the basis of the function intended in the proposed formulation. Based on the intended function, specific controls should be included in the excipient specifications. The assigned excipient function in the original filing will have regulatory implications with respect to post-approval changes depending on the function of the excipient (i.e., recommendations found is SUPAC-IR) (3). An example of a common multifunctional excipient is starch which may be used for multiple purposes (binder, disintegrant, etc.).

Additionally, for complex products (e.g., modified-release products, etc.) with multiple processing steps, it is recommended that the composition of the "intermediates" (e.g. granules, tablet cores or beads) be separated out to reflect each major process step in the composition table for ease of review. Also, it should be clear which ingredients will be added intragranularly or extragranularly. The QbR Frequently Asked Questions (FAQ) document and the Guidance for Industry on Submitting Documentation for the Manufacturing of and Controls for Drug Products provide additional insight (4, 5).

A topic that should also be addressed is related to the chosen dosage form. To be a generic, the dosage form must be the same as the approved RLD unless under an approved suitability petition, and this is clearly one of the main Quality Target Product Profile (QTPP) tenets. With this being said if the RLD is a capsule, the generic must also be a capsule, and also meet the definition in CDER Data Standards Manual (6). Similarly, a formulation may not be called a cream unless it meets the Data Standards Manual (monograph) definition of a cream (6).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here